Medtronic Announces Key Activities at European Society of Cardiology Congress; Major Topics Include Drug-Eluting Stents, Heart Failure and Diagnostic Monitoring of Syncope

"Medtronic continues to develop innovative new products supportedby well-designed clinical trials for a variety of conditions andtherapies," said Bill Hawkins, Medtronic president and chief operatingofficer. "This will be evident at ESC, as physicians present new dataon topics such as the long-term efficacy and safety of theEndeavor(TM) drug-eluting stent, mortality and economic benefits ofcardiac resynchronization therapy (CRT) for heart failure patients,and an integrated diagnosis and treatment strategy for unexplainedfainting."

Medtronic will occupy booth B45 on the ESC exhibit floor at theStockholmsmassan Congress Centre. Following are Medtronic daily eventhighlights:

Sunday, September 4

-- Clinical Trial Update - 17:40-17:55, Copenhagen Room (Green Zone). "Endeavor Clinical Program Update: Long-term Follow-up of ENDEAVOR I and ENDEAVOR II." Prof. Ian Meredith, M.D., Melbourne, Australia, will present 24-month safety and efficacy data on the ENDEAVOR I trial, while Dr. William Wijns, Aalst, Belgium, will present 12-month data from the pivotal ENDEAVOR II trial.

Monday, September 5

-- Hot Line II: - 11:00 - 11:13, Stockholm Room (Green Zone), "Hot Line II: ISSUE II: The Implantable Loop Recorder Allows a Mechanism-Based Effective Therapy in Patients with Recurrent Suspected or Certain Neurally-Mediated Syncope." Dr. Michele Brignole, M.D., FESC, Lavagna, Italy, will present findings from the International Study on Syncope of Uncertain Etiology 2 (ISSUE2), which explored an integrated diagnosis and treatment strategy using the Medtronic Reveal Plus ILR for certain patients who experience episodes of unexplained fainting (syncope).

-- Educational Symposium - 18:30 - 20:00, Bucharest Room (Red Zone), "Long Term Outcomes of the ENDEAVOR Clinical Programme." This physician symposium will offer a comprehensive look at the Medtronic Endeavor drug-eluting stent system, including presentations on: 12-month ENDEAVOR II results, 24-month ENDEAVOR I results, the ENDEAVOR II Continued Access registry and a product overview and perspective. The symposium faculty includes Dr. William Wijns, Dr. Jean Fajadet, Prof. Ian Meredith, Dr. Hans Bonnier and Prof. Martin Rothman.

-- Medical Journal Publication - Twelve-month results from the ENDEAVOR I clinical trial will be published in the European medical journal EuroIntervention and be available at ESC. The article, authored by Prof. Ian Meredith, M.D., is titled "First-in-Human Study of the Endeavor ABT-578-Eluting Phosphorylcholine-Encapsulated Stent System in de novo Native Coronary Artery Lesions: Endeavor I Trial."

Wednesday, September 7

-- Clinical Trial Update - 8:50 - 9:15 Stockholm Room (Green Zone), "CARE-HF: Long-Term Effects of Cardiac Resynchronization on Mortality in the CARE-HF Extension Study." New data about the lifesaving, clinical and economic benefits of device-based CRT from the CARE-HF (Cardiac Resynchronization in Heart Failure) study will be presented by Prof. John G. F. Cleland, M.D., chairman of the CARE-HF steering committee, Prof. Luigi Tavazzi, M.D., and Prof. Nick Freemantle, M.D.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis,is the global leader in medical technology - alleviating pain,restoring health, and extending life for millions of people around theworld.

Any forward-looking statements are subject to risks anduncertainties such as those described in Medtronic's Annual Report onForm 10-K for the year ended April 29, 2005. Actual results may differmaterially from anticipated results.

(Editor's note: Medtronic executives including Scott Ward,president, Medtronic Vascular, and Pat Mackin, vice president,Medtronic Vascular Western Europe, will be available for interviews atESC. To schedule an interview, please contact the Medtronic publicrelations department.)